누낭염 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Dacryocystitis Treatment Market size is expected to reach USD 87.56 Million in 2034 from USD 52.01 Million (2025) growing at a CAGR of 5.96% during 2026-2034.

The global dacryocystitis treatment market is growing due to the increasing prevalence of eye infections and tear duct disorders. Dacryocystitis is an infection of the tear sac that occurs when the tear duct becomes blocked. Treatment typically includes antibiotics, anti-inflammatory medications, and in some cases surgical procedures to restore proper tear drainage.

One of the main drivers of the market is the rising awareness about eye health and the importance of early diagnosis. Improved access to ophthalmic healthcare services has enabled more patients to receive timely treatment for eye infections. Additionally, advancements in minimally invasive surgical procedures are improving treatment outcomes.

Looking ahead, the dacryocystitis treatment market is expected to grow as healthcare providers focus more on specialized eye care services. Technological advancements in ophthalmology and improved diagnostic techniques will support early detection and effective treatment. Increasing healthcare infrastructure in developing regions will also contribute to market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment

• Surgery
• Medication

By Indication

• Chronic Dacryocystitis
• Acute Dacryocystitis
• Congenital Dacryocystitis

By Distribution Channel

• Institutional Sales
• Retail Sales

COMPANIES PROFILED

• AbbVie Inc Allergan, Alcon Inc, Aurolab, Bausch Health Companies Inc, Bayer AG, BVM Medical Limited, F HoffmannLa Roche Ltd Genentech Inc, FCI Ophthalmics, Gunther Weiss Scientific Glassblowing Co Inc, Heart Medical Europe BV, Kaneka Corporation, Merck Co Inc, Novartis AG, Pfizer Inc, Regeneron Pharmaceuticals Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DACRYOCYSTITIS TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment
• 4.2. Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Medication Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DACRYOCYSTITIS TREATMENT MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Chronic Dacryocystitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Acute Dacryocystitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Congenital Dacryocystitis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DACRYOCYSTITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Institutional Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DACRYOCYSTITIS TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Treatment
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Treatment
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Treatment
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Treatment
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Treatment
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL DACRYOCYSTITIS TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie Inc. (Allergan)
  • 9.2.2 Alcon Inc
  • 9.2.3 Aurolab
  • 9.2.4 Bausch Health Companies Inc
  • 9.2.5 Bayer AG
  • 9.2.6 BVM Medical Limited
  • 9.2.7 F. Hoffmann-La Roche Ltd (Genentech Inc.)
  • 9.2.8 FCI Ophthalmics
  • 9.2.9 Gunther Weiss Scientific Glassblowing Co. Inc
  • 9.2.10 Heart Medical Europe BV
  • 9.2.11 Kaneka Corporation
  • 9.2.12 Merck & Co. Inc
  • 9.2.13 Novartis AG
  • 9.2.14 Pfizer Inc
  • 9.2.15 Regeneron Pharmaceuticals Inc